Design and evaluation of controlled release nanoparticles of anticonvulsant drugs to treat status epilepticus

Abstract

One of the life-threatening neurological disorder is specifically the Status epilepticus. Most of antiepileptic drugs used for this epilepsy are not seem to be explore its total effectiveness. Phenytoin could be a classic example and its effectivenessis inhibited by high metabolization (90%-95%) and back transportation through cytochrome P450 and P-glycoprotein, respectively. Apart from this blood brain barrier acts as a neuroprotective barrier for brain.It prevents the entry of harmful substances into the brain. Therefore to meet the above challenge new approach has been done out to boost the effectiveness of phenytoin by adopting nanotechnology and combination drug. To overcome the said issue berberine chloride was taken as a co-drug and it has a anticonvulsant activity. It also act as a Cox-2 inhibitor, cytochrome P-450 inhibitor which helps to maximize the free drug(phenytoin) concentration in plasma by reducing metabolization and back transportation. On account of this Phenytoin and berberinechloride nanoparticles were prepared individually and filled in hard gelatine capsule to make as a single unit dosage form. Using a solvent evaporation technique, phenytoin and berberinechloride nanoparticles were formulated individually and the mixture is then filled into the hard gelatine capsule to create a single-unit dosage. Solubility enhancement and permeability enhancement techniques were also adopted in preformulation study since phenytoin and berberine chloride belongs to class II and class IV category respectively. newline